Sunday, May 21, 2023 12:58:44 PM
Nouveau Life Pharmaceuticals, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
For the Period Ended
March 31, 2023 December 31, 2022
Ordinary Income/Expense
Expense
Advertising and Promotion
107
964.00
Automobile & Travel Expenses
160
1,436.90
Business Licenses and Permits: NV SOS
217
652.00
Bus. Licenses & Permits-Other
7,140
35,700.00
Community Outreach
388
1,165.00
Computer and Internet Expenses
188
562.97
Insurance Expense
128
385.00
Office Supplies
453
1,358.00
Professional Fees
39
352.00
Accounting
232
2,085.00
Business Development
255
2.295.00
Investor Relations
161
1,450.00
Legal
1,250
11,250.00
OTC Markets
3,660
7,429:00
Stock Transfer Agents
667
6,000.00
Rent & Lease Expense
486
4,373.29
Telephone Expense
459.70
Training and Staff Development
205
1,845.00 79,762.86
Total Expense
15,787
Net Ordinary Income
(15.787)
March 31, 2023
(79,762.86)
BASIC AND DILUTED LOSS PER SHARE:
($0.000002)
($0.00001)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic
6,660,963,733
6,660,963,733
The accompanying notes are an integral part of these financial statements.
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM